David E Gerber

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi request reprint Miscellaneous agents--cytotoxics and hormonal agents
    David E Gerber
    Department of Internal Medicine, Division of Hemtology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Thorac Oncol 7:S387-9. 2012
  2. pmc Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts
    David E Gerber
    Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Mail Code 8852, Dallas, TX 75390 8852, USA
    Mol Cancer Ther 11:2473-82. 2012
  3. doi request reprint A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluation
    David E Gerber
    Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Biomed Mater Res A 99:479-84. 2011
  4. pmc ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time
    David E Gerber
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, 75390, USA
    Cancer Cell 18:548-51. 2010
  5. pmc Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy
    David E Gerber
    Department of Internal Medicine, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Thorac Oncol 6:365-71. 2011
  6. doi request reprint Cetuximab in combination therapy: from bench to clinic
    David E Gerber
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 8852, Dallas, TX, 75390 8852, USA
    Cancer Metastasis Rev 29:171-80. 2010
  7. ncbi request reprint Recent advances in radiation therapy
    David E Gerber
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Am Fam Physician 78:1254-62. 2008
  8. ncbi request reprint Targeted therapies: a new generation of cancer treatments
    David E Gerber
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Am Fam Physician 77:311-9. 2008
  9. pmc Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center
    Jeffrey T Yorio
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Clin Lung Cancer 13:448-57. 2012
  10. pmc Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population
    Drew W Rasco
    Department of Internal Medicine Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    J Thorac Oncol 5:1529-35. 2010

Collaborators

Detail Information

Publications28

  1. doi request reprint Miscellaneous agents--cytotoxics and hormonal agents
    David E Gerber
    Department of Internal Medicine, Division of Hemtology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Thorac Oncol 7:S387-9. 2012
    ..Hormonal agents included an aromatase inhibitor (anastrazole), an estrogen receptor antagonist (fulvestrant), and a selective androgen receptor modulator (GTx-024)...
  2. pmc Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts
    David E Gerber
    Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Mail Code 8852, Dallas, TX 75390 8852, USA
    Mol Cancer Ther 11:2473-82. 2012
    ..We conclude that stromal PDGFRα inhibition represents a means for enhancing control of lung cancer growth in some cases, independent of tumor cell PDGFRα expression...
  3. doi request reprint A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluation
    David E Gerber
    Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Biomed Mater Res A 99:479-84. 2011
    ..These results suggest that intracranial R-Gel is well tolerated. Therapeutic studies of chemotherapy-complexed R-Gel are underway...
  4. pmc ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time
    David E Gerber
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, 75390, USA
    Cancer Cell 18:548-51. 2010
    ..Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets...
  5. pmc Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy
    David E Gerber
    Department of Internal Medicine, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Thorac Oncol 6:365-71. 2011
    ..We, therefore, determined the predictors and impact of second-line chemotherapy administration in a contemporary, diverse NSCLC population...
  6. doi request reprint Cetuximab in combination therapy: from bench to clinic
    David E Gerber
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 8852, Dallas, TX, 75390 8852, USA
    Cancer Metastasis Rev 29:171-80. 2010
    ..Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations...
  7. ncbi request reprint Recent advances in radiation therapy
    David E Gerber
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Am Fam Physician 78:1254-62. 2008
    ..As more patients are diagnosed with cancer and as these patients live longer, primary care physicians will increasingly care for those who have received radiation therapy...
  8. ncbi request reprint Targeted therapies: a new generation of cancer treatments
    David E Gerber
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Am Fam Physician 77:311-9. 2008
    ..As more persons are diagnosed with cancer and as these patients live longer, primary care physicians will increasingly provide care for patients who have received targeted cancer therapy...
  9. pmc Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center
    Jeffrey T Yorio
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Clin Lung Cancer 13:448-57. 2012
    ..To explore whether these differences are secondary to individual or institutional characteristics, we examined treatment selection and outcome in a diverse population treated at a single medical center...
  10. pmc Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population
    Drew W Rasco
    Department of Internal Medicine Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    J Thorac Oncol 5:1529-35. 2010
    ..Therefore, we determined the use of chemotherapy in a contemporary, diverse NSCLC population encompassing all patient ages...
  11. pmc Consent timing and experience: modifiable factors that may influence interest in clinical research
    David E Gerber
    University of Texas Southwestern Medical Center, Dallas, TX
    J Oncol Pract 8:91-6. 2012
    ..However, few studies have examined factors related to the consent process. We therefore evaluated the impact of consent timing and experience on markers of patient interest in research...
  12. pmc Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer
    Bercin Kutluk Cenik
    Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Lung Cancer 80:326-32. 2013
    ..To determine how such requirements affect treatment options, we evaluated renal function patterns in this population...
  13. doi request reprint A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
    Jonathan E Dowell
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Lung Cancer 77:567-71. 2012
    ..We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM...
  14. pmc Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer
    David E Gerber
    Department of Internal Medicine, Hematology Oncology, University of Texas Southwestern Medical Center, Dallas 75390 9066, USA
    Patient Educ Couns 89:102-8. 2012
    ..Maintenance chemotherapy is a recently approved approach to the treatment of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' perceptions of maintenance chemotherapy using qualitative methods...
  15. pmc Targeted therapies for lung cancer: clinical experience and novel agents
    Jill E Larsen
    Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Cancer J 17:512-27. 2011
    ..Ongoing research efforts in these areas as well as a discussion of emerging targeted agents being evaluated in clinical trials are the subjects of this review...
  16. doi request reprint Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?
    Jeffrey T Yorio
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    J Thorac Oncol 4:1322-30. 2009
    ..We therefore studied the timing of lung cancer diagnosis and treatment at a U.S. medical center providing care to a diverse patient population within two different hospital systems...
  17. doi request reprint The impact of consenter characteristics and experience on patient interest in clinical research
    Drew W Rasco
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Oncologist 14:468-75. 2009
    ..However, the impact of nonphysician research personnel, who often consent patients for studies, is unclear. We therefore evaluated the association between consenter characteristics and subject interest in clinical research...
  18. doi request reprint Stigma among patients with lung cancer: a patient-reported measurement model
    Heidi A Hamann
    Harold C Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA
    Psychooncology 23:81-92. 2014
    ..This study identified key stigma-related themes to provide a blueprint for item development through a thematic analysis of semi-structured interviews and focus groups with lung cancer patients...
  19. doi request reprint Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer
    Daniel H Ahn
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
    Clin Lung Cancer 14:644-50. 2013
    ..To determine whether medical comorbidities account for these observations, we incorporated a validated medical comorbidity index into an analysis of patients diagnosed with stage I to III NSCLC...
  20. pmc How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience
    Evelyn O Taiwo
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    PLoS ONE 7:e52313. 2012
    ..We therefore evaluated current patterns of early-stage lung cancer presentation...
  21. pmc Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea
    David E Gerber
    Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    J Clin Oncol 31:1009-20. 2013
    ....
  22. doi request reprint Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors
    David E Gerber
    Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Clin Cancer Res 17:6888-96. 2011
    ..This phase I study assessed the safety and pharmacokinetics of bavituximab in patients with advanced solid tumors...
  23. pmc BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer
    Bercin Kutluk Cenik
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Mol Cancer Ther 12:992-1001. 2013
    ..The absence of EMT induction, which has been implicated in resistance to antiangiogenic therapies, is noteworthy. Together, these results warrant further clinical studies of BIBF 1120...
  24. pmc Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies
    Puneeth Iyengar
    Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Cancer J 19:247-62. 2013
    ....
  25. doi request reprint Maintenance therapy for advanced lung cancer: who, what, and when?
    David E Gerber
    Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Clin Oncol 31:2983-90. 2013
    ..After four cycles of chemotherapy, a chest CT showed ongoing response (Fig 2D). Her Eastern Cooperative Oncology Group performance status remained 0. ..
  26. doi request reprint Targeting the PI3K pathway for cancer therapy
    Navid Sadeghi
    Division of Hematology and Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Future Med Chem 4:1153-69. 2012
    ..This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment...
  27. doi request reprint Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment
    Paul DeRose
    Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Immunotherapy 3:933-44. 2011
    ..This article summarizes the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer...
  28. ncbi request reprint Emerging monoclonal antibody therapies for malignant gliomas
    David E Gerber
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Baltimore, Maryland, USA
    Expert Opin Investig Drugs 16:477-94. 2007
    ..Previous experience with mAbs in other malignancies may provide guidance for their use in the treatment of CNS malignancies...